Skip to main content

Table 4 Univariable and multivariable analysis of OS according to various prognostic groups

From: Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Variable

Univariable analysis

Multivariable analysis

HR (95% CI)

P-value

HR (95% CI)

P-value

Treatment Arm

    

(A vs. B)

1.56 (0.60 to 4.16)

0.361

  

Age (>50 vs. ≤50)

1.45 (0.56 to 3.75)

0.441

  

IDC vs. ILC

1.34 (0.45 to 5.49)

0.462

  

Grade (3 vs1/2)

1.79 (0.67 to 4.81)

0.244

  

ER (+) vs. (−)

0.53 (0.21 to 1.35)

0.188

  

PR (+) vs. (−)

0.31 (0.11 to 0.89)

0.030

0.31 (0.10 to 1.19)

0.071

HER2 (+) vs. (−)

1.22 (0.45 to 3.26)

0.692

  

TN (yes) vs. (no)

1.75 (0.65 to 4.65)

0.267

  

Ki67 (High) vs. (Low)

1.47 (0.50 to 4.16)

0.480

  

pCR vs. non pCR

2.21 (0.88 to 6.64)

0.080

1.42 (0.08 to 2.32)

0.801

ALDH1 (+) vs. (−)

    

 Baseline

1.10 (0.43 to 2.81)

0.831

  

 Post NAC*

10.58 (1.65 to 14.68)

0.005

4.61 (1.30 to 23.00)

0.024

  1. ALDH1, aldehyde dehydrogenase-1; pCR, complete pathologic response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; TN, triple negative. *Post NAC, patients include ALDH1(−) as well as those with pCR.